

Registration
www.meeting-com.ch

Final
Program



49th Annual Meeting Swiss Society of Nephrology

Forum Fribourg, Granges-Paccot
December 7-8, 2017

Schweizerische Gesellschaft für Nephrologie
Société Suisse de Néphrologie
Società Svizzera di Nefrologia

Symposia

December 6, 2017

Basics in Nephrology

December 8, 2017

Pflege in der Nephrologie / Soins en Néphrologie /
Cure in Nefrologia

NEPHRO
SWISS SOCIETY OF NEPHROLOGY

www.swissnephrology.ch

Table of contents

| | |
|--|----|
| Invitation 2017 | 3 |
| Organization | 4 |
| General information | 5 |
| Program at a glance | 8 |
| Scientific Program – Basics in Nephrology | 11 |
| Scientific Program | 12 |
| Congress Dinner | 22 |
| Scientific Program & Pflege in der Nephrologie | 23 |
| Poster presentations | 33 |
| Speakers / Moderators | 44 |
| Exhibitors | 47 |
| Sponsored symposia in alphabetical order | 48 |
| Sponsors | 49 |
| SGN-SSN congress 2018 | 51 |

Invitation 2017

Dear Colleagues,

It's a pleasure to invite you to the 49th annual meeting of the Swiss Society of Nephrology in Fribourg. This is the first time that we have the meeting at Fribourg and we hope that its central location will facilitate your participation.

The 2017 meeting is a continuum of the evolution of the precedent meetings. We are introducing this year the sponsored lectures which is another way to collaborate with our partners from the industry. We will have 4 sponsored lectures in addition to 5 satellite symposia which will cover different fields of interest in Nephrology.

The CME will be focused on peritoneal dialysis with some theoretical lectures but also some case reports to illustrate specific clinical situations.

The first state of the art lecture will be on thirst and will be given by Daniel Bichet from Montreal.

The second state of the art lecture on Home dialysis will be given by Eric Goffin, from Bruxelles.


As usual, we will have nephropathology and genetic inherited kidney diseases sessions and a session dedicated to NCCR, a consortium which is very active and a leader in renal physiology and pathophysiology.

Finally, we encourage you to attend to oral presentations and to poster sessions which are selected amongst the abstracts presented by our members. The scientific activity of the swiss nephrology community is outstanding and these sessions are organized to present this activity to SSN members. A poster walk is organised Thursday evening.

Friday, we will have nurses-oriented sessions. We have selected themes which concern both nephrology nurses and nephrologists.

I am eager to see you at Fribourg and to share with you the progresses that are done in our specialty.

Congress president SGN-SSN



Pierre-Yves Martin

Organization

Congress President

Pierre-Yves Martin, Geneva

Scientific Committee

Patrizia Amico, Basel
 Spyridon Arampatzis, Bern
 Sophie De Seigneux, Geneva
 Thomas Ernandez, Geneva
 Eric Féraille, Geneva
 Déla Golshayan, Lausanne
 Karine Hadaya, Geneva
 Nilufar Mohebbi, Zürich
 Thomas Müller, Zürich
 Belen Ponte, Geneva
 Menno Pruijm, Lausanne
 Fabien Stucker, Neuchâtel
 Jean Villard, Geneva
 Carsten Wagner, Zürich
 Grégoire Würzner, Lausanne

Board of the SGN-SSN

President 2016-2017

Pierre-Yves Martin, HUG, Geneva

President-elect

Uyen Huynh-Do, Inselspital, Bern

Secretary

Olivier Bonny, CHUV, Lausanne

Treasurer

Patrick Wilson, Hôpital du Jura, Delémont

Pediatric Nephrologist

Thomas J. Neuhaus, Kinderspital LUKS, Luzern

Dialysis Commission

Dominik E. Uehlinger, Inselspital, Bern

Board Members

Isabelle Binet, Kantonsspital, St. Gallen
 Andreas Bock, Kantonsspital, Aarau
 Olivier Devuyst, Institute of Physiology, Zürich
 Daniel Fuster, Inselspital, Bern
 Luca Gabutti, Ospedale Regionale, Bellinzona
 Ann-Kathrin Schwarzkopf, Hirslanden Bern AG, Bern

General information

Congress venue

Forum Fribourg Expo Centre SA

Route du Lac 12, 1763 Granges-Paccot
www.forum-fribourg.ch

Registration & congress secretariat

Meeting-com Congress Organisation

Rue des Pâquis 1, CH-1033 Cheseaux-sur-Lausanne
 Online registration on: www.meeting-com.ch
 T +41 21 312 9261 – F +41 21 312 9263 – E info@meeting-com.ch
 Onsite registration also possible (onsite fee)

Registration fees for SGN congress

| | Early fee (before Nov. 1, 2017) | Late fee (Nov. 2-29, 2017) | Onsite fee (From Nov. 30, 2017) |
|---------------------------|------------------------------------|-------------------------------|------------------------------------|
| Member SGN | CHF 230.00 | CHF 270.00 | CHF 300.00 |
| Non-member SGN | CHF 280.00 | CHF 320.00 | CHF 360.00 |
| Residents/Students* | CHF 150.00 | CHF 180.00 | CHF 210.00 |
| Pflege in der Nephrologie | CHF 100.00 | CHF 120.00 | CHF 150.00 |
| NCCR-Member | CHF 150.00 | CHF 180.00 | CHF 210.00 |

* Confirmation of status for residents/ student required to be sent to F 021 312 92 63 or to nicole.giacomini@meeting-com.ch.

Registration fees for Symposium 6.12.17

| | Early bird fee (before Nov. 1, 2017) | Late fee (Nov. 2-29, 2017) | Onsite fee (From Nov. 30, 2017) |
|----------------------|---|-------------------------------|------------------------------------|
| Basics in Nephrology | CHF 100.00 | CHF 120.00 | CHF 150.00 |

Congress Dinner 7.12.17 CHF 90.00 (places limited)

Included in the registration fees

Access to the scientific sessions, congress documents, certificate of participation, coffee breaks and lunches.
Accommodation not included.

Payment

Upon registration, you will receive a confirmation by email together with the banking details for the payment.
 Payment by credit card upon registration is possible.

General information

| | |
|-------------------------------------|---|
| Congress management | Meeting.com Congress Organisation Mrs Nicole Giacomini Rue des Pâquis 1, CH-1033 Cheseaux-sur-Lausanne T +41 21 312 9161, F +41 21 312 9263 nicole.giacomini@meeting-com.ch , www.meeting-com.ch |
| Certificate of participation | The certificate of participation will be sent in pdf form to the participants after the event. |
| Cancellation | Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CHF 60.00 for administrative costs. Thereafter no refund possible. Any registration made within the "early bird" time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne. |
| Industrial exhibition | An industrial exhibition will take place at the Congress Venue. It will be open throughout the congress. Coffee (breaks) will be offered by exhibitors. |
| Hotel booking | Hotel reservation possible with Fribourg Tourismus on www.fribourgtourisme.ch . |
| Bus | Forum Fribourg is reachable by bus nr 1, direction "Portes-de-Fribourg" |
| WIFI | Name SGN2017 Password Congress |
| Parking | A parking is available at Forum Fribourg. Daily tickets will be sold at the welcome desk at the price of CH 10.00/day |

General information

| | |
|----------------------------|--|
| Oral Presentations | The abstracts accepted as oral communication will be presented in the Oral Parallel Presentations. Speaking time : 8 min and 2 min discussion. |
| Posters | The abstracts accepted as poster will be presented in the poster exhibition. Dimensions of posters : height 120 cm x width 90 cm (portrait). |
| Posterwalk | There will be an organized Posterwalk on Thursday, December 7, 2017, from 17 h 45 to 18 h 30 where the highest rated posters in each category will receive the Poster Prize Award : – Clinical Nephrology /Hypertension /Mineral/ Electrolytes – Basic Science /Genetics /Experimental Nephrology – Hemodialysis (HD)/Peritoneal Dialysis (PD) – Transplantation we thank each author to be present near his/her poster during the posterwalk |
| Poster Prize Awards | will take place during the Congress Dinner on December 7, 2017. |
| Registration | Authors presenting an accepted paper or poster must register to attend the meeting and pay the appropriate registration fee. |
| Credits | Credits points will be given by the following societies : SGN-SSN Congress, December 7-8, 2017 SGN-SSN 16 credits SGAIM-SSMIG 10 credits Basics in Nephrology, December 6, 2017 SGN-SSN 4 credits SGAIM-SSMIG 4 credits |
| Language | Lectures in English, discussion in German, French or English. The Symposium "Pflege in der Nephrologie" will be held in German, French and Italian |

Program at a glance

Wednesday, December 6, 2017

| Special CME Symposium Basics in Nephrology Course | |
|--|---------------------------------------|
| Schedule | Room 3E |
| From 12.00 | Registration |
| 13.00-15.00 | Plenary sessions |
| 15.00-15.30 | Coffee Break |
| 15.30-17.30 | Plenary sessions |
| 17.30 | End of Basics in Nephrology Course |

Program at a glance

Thursday, December 7, 2017

| Schedule | Room A | Room B |
|-------------|--|---|
| From 8.00 | Registration | |
| 09.45-09.50 | Welcome Address | |
| 09.50-10.45 | State of the Art Lectures | |
| 10.45-11.15 | Coffee break – Visit of the exhibition – Poster viewing | |
| 11.15-12.15 | Oral Parallel Presentations Basic Science/Genetics/ Experimental Nephrology | Oral Parallel Presentations Transplantation |
| 12.15-12.30 | Short break | |
| 12.30-13.15 | Satellite Lunch Symposium Sponsored by AMGEN | |
| 13.15-14.00 | Standing lunch at the exhibition – Poster viewing | |
| 14.00-15.00 | Sponsored lecture by ALEXION | Symposium NCCR Kidney.CH |
| 15.00-15.30 | Coffee break – Visit of the exhibition | |
| 15.30-16.15 | Parallel Satellite Symposium Sponsored by BAXTER | Parallel Satellite Symposium Sponsored by OTSUKA |
| 16.15-16.30 | Short break | |
| 16.30-17.40 | Parallel Symposium Nephropathology | Parallel Symposium WGIKD |
| 17.45-18.30 | Posterwalk in the Exhibition | |
| 19.45 | WELCOME DRINK & CONGRESS DINNER with Poster Prize Awards | |

Program at a glance

Friday December 8, 2017

| Schedule | Room A | Room B | Room 3E |
|-------------|---|---|---|
| From 07.00 | Registration | | |
| 07.45-09.15 | General assembly SGN-SSN | | |
| 09.15-09.45 | The Swiss Dialysis Registry | | |
| 09.45-10.00 | SGN-SSN Publication Award 2017 | | |
| 10.00-10.15 | Short break | | 09.30-11.00 Pflege in der Nephrologie |
| 10.15-11.00 | Satellite Symposium Sponsored by VIFOR | | |
| 11.00-11.30 | Coffee break – Visit of the exhibition – Poster viewing | | |
| 11.30-12.15 | Sponsored lecture by BAXTER | | 11.30-12.15 Pflege in der Nephrologie |
| 12.15-12.30 | Short break | | |
| 12.30-13.15 | Satellite Symposium Sponsored by ASTELLAS | | 12.30-13.15 Pflege in der Nephrologie |
| 13.15-14.00 | Standing lunch at the exhibition – Poster viewing | | |
| 14.00-15.00 | Oral Parallel Presentations Clinical Nephrology / Hypertension / Mineral / Electrolytes | Oral Parallel Presentations Hemodialysis (HD) / Peritoneal Dialysis (PD) | |
| 15.00-15.30 | Coffee break – Visit of the exhibition – Poster viewing | | |
| 15.30-16.30 | Hot Topics | | |
| 16.30 | Farewell | | |

Wednesday, December 6

Room 3E

Satellite CME Symposium: Basics in Nephrology

Peritoneal Dialysis

| | |
|--------------------|---|
| From 12.00 | Registration |
| 13.00-13.40 | Physiology of the peritoneal membrane Olivier Devuyst, Zurich |
| 13.40-14.20 | Peritoneal membrane transport characteristics and dialysis adequacy assessment in PD Thomas Hernandez, Geneva |
| 14.20-15.00 | Initial prescription in PD Andreas Fischer, Lucerne |
| 15.00-15.30 | Coffee break |
| 15.30-16.10 | Infectious complications in PD Valérie Jotterand Drepper, Geneva |
| 16.10-16.50 | Non-infectious complications in PD Catherine Stoermann-Chopard, Geneva |
| 16.50-17.30 | PD in practice (clinical cases discussion) Georges Halabi, Lausanne |
| 17.30 | End of Basics in Nephrology Course |

Thursday, December 7

Swiss Society of Nephrology Congress

| | | |
|-------------|--|------------------|
| From 08.00 | Registration | |
| 09.45 | Opening of the 49th Annual Meeting of the Swiss Society of Nephrology | Room A |
| 09.45-09.50 | Welcome Address Pierre-Yves Martin, Geneva; Daniel Hayoz, Fribourg | |
| 09.50-10.45 | State of The Art Lectures THIRST <i>Chairs: Pierre-Yves Martin, Geneva; Daniel Hayoz, Fribourg</i> Daniel G. Bichet, Montreal (CA) | Room A |
| 10.45-11.15 | Coffee break – Visit of the exhibition – Poster viewing | Exhibition space |
| 11.15-12.15 | Oral Parallel Presentations | |
| 11.15-12.15 | Basic Science / Genetics / Experimental Nephrology <i>Chairs: Olivier Bonny, Lausanne; Nilufar Mohebbi, Zurich</i> 6 oral presentations | Room A |
| 11.15-12.15 | Transplantation <i>Chairs: Patrizia Amico, Basel; Jean Villard, Geneva</i> 6 oral presentations | Room B |
| 12.15-12.30 | Short break | |

Oral communications

Oral Parallel Presentations

| | | |
|-------------|---|---------------|
| 11.15-12.15 | Basic Science / Genetics / Experimental Nephrology <i>Chairs: Olivier Bonny, Lausanne; Nilufar Mohebbi, Zurich</i> | Room A |
| OC 07 | The deubiquitinase OTUB1 in kidney injury and fibrosis (NCCRproject) Ms. Julia Günter ¹ , Ms. Amalia Ruiz-serrano ¹ , Dr. Svende Pfundstein ¹ , Prof. Roland Wenger ¹ , Dr. Cwarsten Scholz¹ ¹ University of Zurich | |
| OC 08 | Low β-catenin expression levels during development alter renal morphology and function (NCCR Project) Dr. Stefan Rudloff¹ , Dr. Delphine Lambert ¹ , Ms. Andrea Karolin ¹ , Ms. Andrea Bileck ¹ , Prof. Uyen Huynh-Do ¹ ¹ University Hospital Bern | |
| OC 09 | Protein phosphatase 1 inhibitor 1 mediates cAMP-dependent stimulation of the renal NaCl cotransporter Dr. David Penton Ribas¹ , Ms. Sandra Moser ¹ , Ms. Agnieszka Wengi ¹ , Dr. Jan Czogalla ¹ , Dr. Lena Lindtoft Ronsenbaek ² , Dr. Nourdine Faresse ¹ , Prof. Robert Fenton ² , Dr. Dominique Loffing ¹ , Prof. Johannes Loffing ¹ ¹ University of Zurich, ² University of Aarhus, Aarhus, Denmark | |
| OC 10 | Localization and role of uromodulin in the distal convoluted tubule Dr. Natsuko Tokonami¹ , Dr. Tomoaki Takata ¹ , Mr. Jan Beyeler ¹ , Prof. Johannes Loffing ¹ , Prof. Olivier Devuyst ¹ , Dr. Eric Olinger ¹ ¹ University of Zurich | |
| OC 11 | Sex-hormone regulation of uric acid homeostasis Dr. Muriel Auberson¹ , Ms. Fanny Durussel ¹ , Prof. Olivier Bonny ² ¹ University of Lausanne, ² University Hospital (CHUV) and University of Lausanne | |
| OC 12 | Absence of HIF pathway activation during chronic kidney disease (CKD): a pathway to anemia (NCCR project) Mr. Romain Dissard¹ , Ms. Frederique Ino ¹ , Ms. Vasiliki Delitsikou ¹ , Prof. Sophie De Seigneux ² ¹ University of Geneva, ² University Hospital Geneva | |

Oral communications

Oral Parallel Presentations

11.15-12.15

Transplantation

Chairs: Patrizia Amico, Basel; Jean Villard, Geneva

Room B

OC 19

Clinical long-term outcomes of kidney transplantation from pediatric donors

Dr. Yvonne Holzmann¹, Dr. Argyrios Georgalis¹, Dr. Caroline Wehmeier¹, Dr. Patricia Hirt-Minkowski¹, Mr. Gideon Hönger¹, Dr. Helmut Hopfer¹, Prof. Lorenz Gürke¹, Prof. Jürg Steiger¹, Prof. Stefan Schaub¹, Dr. Patrizia Amico¹

¹University Hospital Basel

OC 20

Aryl hydrocarbon receptor expression by macrophages and lymphocytes within infiltrates in BK Polyomavirus associated nephropathy

Dr. Yassine Bouatou¹, Dr. Geurt Stokman², Dr. Nike Claessen², Dr. Joris Roelofs², Prof. Frederike Bemelman², Dr. Jesper Kers², Prof. Sandrine Florquin²

¹AMC/Geneva University Hospitals, Geneva, ²AMC, Amsterdam, Netherlands

OC 21

Adherence and tolerability of prolonged-release tacrolimus in stable kidney and liver transplant patients after conversion from immediate-release tacrolimus in routine clinical practice: the IMPROVE study

Dr. Marco Bonani¹, Dr. Alexandre Balaphas², Dr. Giulia Bedino³, Prof. Léo Bühler², Dr. Philipp Dutkowski¹, Dr. Kathrin Fausch⁴, Dr. Silvia Gluderer⁵, Dr. Nicole Graf⁶, Dr. Patricia Hirt-Minkowski⁷, Prof. Beat Müllhaupt¹, Dr. Carlo Schönholzer³, Dr. Martin Schulz⁵, Dr. Reto Venzin⁴, Prof. Rudolf P. Wüthrich¹

¹University Hospital Zurich, ²University Hospital Geneva, ³Lugano Regional Hospital, Lugano, ⁴Cantonal Hospital Graubünden, Chur, ⁵Astellas Pharma AG, Wallisellen, ⁶Graf Biostatistics, Winterthur, ⁷University Hospital Basel

Oral communications

OC 22

Long-term outcomes after BK Polyomavirus replication in renal allograft recipients

Ms. Nicole Bischof¹, Prof. Hans Hirsch¹, Dr. Caroline Wehmeier¹, Dr. Patrizia Amico¹, Prof. Michael Dickenmann¹, Dr. Patricia Hirt-Minkowski¹, Prof. Jürg Steiger¹, Dr. Thomas Menter¹, Dr. Helmut Hopfer¹, Prof. Stefan Schaub¹

¹University Hospital Basel

OC 23

Immunosuppressive drugs used to treat acute antibody-mediated rejection in kidney transplant recipients of the Swiss Transplant Cohort Study (STCS)

Dr. Nancy Perrottet Ries¹, Dr. Dela Golshayan², Dr. Samuel Rotman¹, Dr. Solange Moll³, Dr. Helmut Hopfer⁴, Mrs. Emmanuelle Catana¹, Dr. Michael Koller⁴, Dr. Jean-pierre Venetz², Dr. Vincent Aubert¹, Dr. Oriol Manuel², Prof. Léo Bühler⁵, Dr. Karine Hadaya⁶, Prof. Thomas Mueller⁷, Prof. Uyen Huynh-Do⁸, Dr. Isabelle Binet⁹, Prof. Michael Dickenmann⁴, Prof. Jürg Steiger⁴, Prof. Manuel Pascual²

¹University Hospital (CHUV), Lausanne, ²University Hospital (CHUV) and University of Lausanne, ³Geneva University Hospital and Medical School, Geneva, ⁴University Hospital Basel, ⁵Geneva University Hospitals and Medical School, Geneva, ⁶Geneva University Hospitals, Geneva, ⁷Universitätsspital Zürich, ⁸Inselsspital Bern, ⁹Cantonal Hospital St Gallen

OC 24

Review of studies on changes in renal physiology induced by nephrectomy in living donors (NCCR project)

Dr. Andreja Figurek¹, Prof. Valerie Luyckx¹, Dr. Seraina Von Moos¹, Prof. Thomas Mueller¹

¹University Spital Zürich

AMGEN[®]

invites you to a Scientific Lunch Symposium

Innovation with impact: Calcimimetics for secondary HPT

Lunch
 will be
 provided

Thursday 7 December 2017
 12:30 – 13:15

Chair

Prof. Dr. med. Michel Burnier
 CHUV Lausanne, Switzerland

Speakers

Prof. Dr. med. Sophie De Seigneux
 Hôpitaux Universitaires Genève, Switzerland

**Past, present and future: the continuing challenge of
 CKD-MBD to reach targets in secondary HPT**

Prof. Dr. med. Andreas Bock
 Kantonsspital Aarau, Switzerland

**Etelcalcetide – What does the
 clinical study data show?**

AMGEN[®]

AMGEN Switzerland AG, Dammstrasse 21, 6301 Zug, www.amgen.ch

SC-CH-CP-00039

Thursday, December 7

| | | |
|-------------|---|---|
| 12.30-13.15 | Satellite Lunch Symposium Sponsored by AMGEN <i>Chair: Michel Burnier, Lausanne</i> |  Room A |
| | Past, present and future: the continuing challenge of CKD-MBD to reach targets in secondary HPT Sophie de Seigneux, Geneva Etelcalcetide – What does the clinical study data show? Andreas Bock, Aarau | |
| 13.15-14.00 | Standing lunch at the exhibition – Poster viewing | Exhibition space |
| 14.00-15.00 | Parallel Symposia 14.00-15.00 Novel insight about complement dysregulation and diagnostic challenges Sponsored lecture by ALEXION <i>Chairs: Karine Hadaya, Geneva; Andreas Kistler, Frauenfeld</i> Daniel Ricklin, Basel; Sacha Zeerleder, Amsterdam (NL) |  Room A |
| 14.00-15.00 | Symposium NCCR Kidney.CH <i>Chairs: Johannes Loffing, Zürich; Carsten Wagner, Zürich</i> | Room B |
| 14.00-14.20 | The deubiquitinase OTUB1 in kidney injury and fibrosis Carsten Scholz, Zürich | |
| 14.20-14.40 | Long non-coding RNAs mediate regeneration of acute kidney injury Johan Lorenzen, Zürich | |
| 14.40-15.00 | Computers & physiology – Modeling renal & cardiac function Diane de Zélicourt, Zürich | |
| 15.00-15.30 | Coffee break – Visit of the exhibition – Poster viewing | Exhibition space |

GET CONNECTED TO...

...PATIENTS ON HOME DIALYSIS

Thursday, December 7

15.30-16.15 **Parallel Satellite Symposium**
Sponsored by **BAXTER** **Baxter** **Room A**

PD - Start Strong & Stay Strong
Chair: Valérie Jotterand Drepper, Geneva, CH

15.30-15.50 **Improving PD Outcomes**
Mark Lambie, Stokes (GB)

15.50-16.10 **Impact of Remote Patient Management (RPM) in PD**
Rizwan Hamer, Coventry (UK)

16.10-16.15 **Discussions**

15.30-16.15 **Parallel Satellite Symposium**
Sponsored by **OTSUKA** **Otsuka** **Room B**

Welcome & Introduction
Michel Burnier, Lausanne
Insights into the clinical evidence for Tolvaptan and on imaging in ADPKD
Andreas Kistler, Frauenfeld
Insights from the real world setting
Daniel Fuster, Bern

Q&A session moderated by
Michel Burnier, Lausanne

16.15-16.30 Short break

Parallel Satellite Symposium: Thursday, December 7 2017; 15.30 – 16.15 (Room A)

PD – START STRONG & STAY STRONG

Chair: Valérie Jotterand Drepper, Geneva

Speakers:

Improving PD Outcomes – **Mark Lambie**, Stokes (UK)

Impact of Remote Patient Management (RPM) in PD – **Rizwan Hamer**, Coventry (UK)

Sponsored lecture: Friday, December 8 2017; 11.30 – 12:15 (Room A)

HOME DIALYSIS: SITUATION IN EUROPE

Chairs: Dominik Uehlinger, Bern and Andreas Bock, Aarau

Speaker: **Eric Goffin**, Bruxelles (BE)

Baxter

Baxter AG, Thurgauerstr. 130, 8152 Glattpark (Opfikon)



Endlich! Licht in Sicht bei ADPKD.

JINARC® – Die erste krankheitsmodifizierende Therapie für Patienten mit autosomal-dominanter polyzystischer Nierenerkrankung (ADPKD)* 1,2

- reduziert die Zunahme des Nierenvolumens¹
- verlangsamt die Abnahme der renalen Funktion¹
- mindert das Risiko von ADPKD-assoziierten Schmerzen¹



* Ausführliche Informationen zur Kasenzulassung entnehmen Sie bitte der Spezialistenliste unter www.spezialistenliste.ch
 * Erwachsene mit chronischer Nierenerkrankung (CKD) im Stadium 1 bis 3 zu Behandlungsbeginn mit Anzeichen für rasch fortschreitende Erkrankung²

Referenzen:
 1. Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2012; 367: 2407–2416.
 2. Fachinformation Jinarc®: www.swissmedicinfo.ch

JINARC® (Tolvaptan) Kurzfachinformation. Indikation: Verlangsamung der Progression von Zystenentwicklung und Nierenineffizienz bei autosomal-dominanter polyzystischer Nierenerkrankung (ADPKD) bei Erwachsenen mit chronischer Nierenerkrankung (CKD) (Stad. 1 - 3 zu Behandlungsbeginn) mit Anzeichen für rasch fortschreitende Erkrankung. **Dosierung:** 2 x täglich als geteilte Dosis von 45 mg + 15 mg (Anfangsdosis), Dosisstabilisation auf 60 mg + 30 mg oder 90 mg + 30 mg. Die Patienten müssen die höchste verträgliche Dosis Tolvaptan erhalten. Die Tolvaptan-Therapie darf nur von Ärzten eingeleitet und beaufsichtigt werden, die Erfahrung in der Behandlung von ADPKD haben und denen die Risiken einer Tolvaptan-Behandlung einschließlich der Hepatotoxizität sowie die notwendigen Überwachungsmaßnahmen vollumfänglich bekannt sind. **Kontraindikation:** Überempfindlichkeit gegen den Wirkstoff oder sonstige Bestandteile; erhöhte Leberenzyme u./o. Anzeichen oder Symptome einer Leberschädigung vor der Einleitung der Behandlung, die die Anforderungen für ein dauerhaftes Absetzen von Tolvaptan erfüllen; Volumendepletion; Hypermatriämie; Patienten, die Durst nicht wahrnehmen, oder auf Durst nicht reagieren können; Schwangerschaft; Stillzeit. **Warnhinweise und Vorsichtsmaßnahmen:** Tolvaptan wurde mit idiosyncratischen Zunahmen der Alanin- und Aspartat-Aminotransferase (ALT und AST) Spiegel und in seltenen Fällen mit einer gleichzeitigen Erhöhung des Gesamtbilirubins (BT) in Verbindung gebracht. Um das Risiko von erheblichen und/oder irreversiblen Leberschäden zu verringern, sind Bluttests zur Bestimmung der Lebertransaminasen und des Bilirubins vor Beginn der Behandlung mit Jinarc, danach monatlich für 18 Monate und danach regelmäßig alle 3 Monate erforderlich. Die gleichzeitige Überwachung auf Symptome, die auf Leberschäden hinweisen können (wie Müdigkeit, Appetitlosigkeit, Übelkeit, Beschwerden im rechten Oberbauch, Erbrechen, Fieber, Hautausschlag, Juckreiz, dunkler Urin oder Gelbsucht), wird empfohlen. Dehydrierung, Harnausflussobstruktion, Flüssigkeits- und Elektrolythaushalt, abnormale Serumnatriniumspiegel, Anaphylaxie, Diabetes mellitus, erhöhte Harnsäurewerte, CYP3A- und P-gp-Induktoren. **Interaktionen:** Mässige oder starke CYP3A-Inhibitoren; starke CYP3A- und P-gp-Induktoren; CYP3A-, CYP2C9-, P-gp- und Transporter-Substrate; Diuretika oder nicht diuretische Antihypertensiva; Vasopressin-Analoga. **Unerwünschte Wirkungen:** sehr häufig: Polydipsie, Kopfschmerzen, Schwindel, Durchfall, Mundtrockenheit, Nykturie, Pollakisurie, Polyurie, Müdigkeit, Durst; häufig: Dehydratation, Hypermatriämie, vermindelter Appetit, Hyperurikämie, Hyperglykämie, Schlaflosigkeit, Herzklopfen, Dyspnoe, Blähungen, Verstopfung, Dyspepsie, gastroösophageale Refluxkrankheit, gestörte Leberfunktion, Exanthem, Juckreiz, Muskelkrämpfe, Asthenie, erhöhte Alanin-Aminotransferase, erhöhte Aspartat-Aminotransferase, Gewichtsabnahme. **Packungen:** 28 Tabletten: 15, 30 mg Tolvaptan. 56 Tabletten: 28 x 45 mg + 28 x 15 mg Tolvaptan. 56 Tabletten: 28 x 60 mg + 28 x 30 mg Tolvaptan. 56 Tabletten: 28 x 90 mg + 28 x 30 mg Tolvaptan. Konsultieren Sie bitte vor einer Verschreibung die vollständige Fachinformation, die auf der Homepage von Swissmedic unter www.swissmedicinfo.ch publiziert ist. **Abgabekategorie:** A, **Zulassungsinhaber:** Otsuka Pharmaceutical (Switzerland) GmbH, Sägereistrasse 20, 8152 Glattbrugg, Stand: Februar 2016 (v001).

Thursday, December 7

| | | |
|-------------|--|---------------|
| 16.30-17.30 | Parallel Symposia | |
| 16.30-17.30 | Nephropathology <i>Chairs: Solange Moll, Geneva; Helmut Hopfer, Basel</i> | Room A |
| 16.30-16.45 | Lupus nephritis: what's new about histopathological scoring? Ariana Gaspert, Zürich | |
| 16.45-17.00 | IgA GN: what's new about histopathological Oxford classification? Vera Genitsch-Gratwohl, Bern | |
| 17.00-17.15 | Banff classification: an update Samuel Rotman, Lausanne | |
| 17.15-17.30 | Biopsy findings in patients after stem cell transplantation Thomas Menter, Basel | |
| 16.30-17.40 | Symposium WGIKD <i>Chairs: Olivier Devuyst, Zürich; Uyen Huynh-Do, Bern</i> | Room B |
| 16.30-16.50 | Basic sciences lysosomes and PT function Olivier Devuyst, Zürich | |
| 16.50-17.10 | Case presentation Cystinosis Sibylle Tschumi, Bern | |
| 17.10-17.40 | Fabry Diseases - Inherited Kidney Diseases Sponsored lecture by SHIRE Christine Kurschat, Koeln (DE) | |

| | | |
|-------------|--|--------------------|
| 17.45-18.30 | Poster walk | Poster Area |
| Topics | – Clinical Nephrology / Hypertension / Mineral / Electrolytes | |
| Jury | Sophie de Seigneux, Geneva; Belen Ponte, Geneva | |
| Topics | – Basic science / Genetics / Experimental Nephrology | |
| Jury | Eric Féraille, Geneva; Nilufar Mohebbi, Zürich | |
| Topics | – Hemodialysis (HD) / Peritoneal Dialysis (PD) | |
| Jury | Thomas Hernandez, Geneva; Menno Pruijm, Lausanne | |
| Topic | – Transplantation | |
| Jury | Karine Hadaya, Geneva; Thomas Müller, Zürich | |

19.45 **WELCOME DRINK & CONGRESS DINNER** **Room A**
Poster Prize Awards

Thursday, December 7

Room A

CONGRESS DINNER

19.45 **WELCOME DRINK & CONGRESS DINNER**
Poster Prize Awards



The Forum Fribourg will provide a perfect setting for the Congress Dinner of the Swiss Society of Nephrology. Enjoy a unique atmosphere, combined with first-class service and excellent cuisine.

We await your reservation with pleasure when registering online on www.meeting-com.ch. Pre-reservation is highly recommended. Additional tickets will be available at the registration desk on a first come first served basis.

Price: CHF 90.00/ticket

Forum Fribourg – Route du Lac 12, 1763 Granges-Paccot

Friday, December 8

Swiss Society of Nephrology Congress

Special Satellite Symposium: Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia

Sprache: französisch

Slides und Fragen: auch auf deutsch und italienisch

From 07.00 Registration

07.45-09.15 **GENERAL ASSEMBLY SGN-SSN**

09.15-09.45 **The Swiss Dialysis Registry**
Patrice Ambühl, Zürich
Chair: Pierre-Yves Martin, Geneva

09.45-10.00 **SGN-SSN Publication Award 2017**
Chair: Pierre-Yves Martin, Geneva
Presentation and short address
Olivier Bonny, CHUV, Lausanne
Renal Fanconi Syndrome and Hypophosphatemic Rickets in the Absence of Xenotropic and Polytopic Retroviral Receptor in the Nephron



09.30-11.00 **Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia**

Health literacy and shared decision making: Room 3E
– un programme d'éducation thérapeutique en néphrologie
– Programm für therapeutische Patientenschulung in der Nephrologie
– un programma di formazione terapeutica in nefrologia
Pascale Lefuel, Infirmière spécialiste clinique en néphrologie, Geneva ;
Anne Dufey-Teso, Néphrologue, Geneva

10.00-10.15 Short break

Room A

Room A

Room A

Room 3E

Hyperkalemia Management in Cardio-renal Patients

SGN/SSN Congress – Forum Fribourg, Room A
Friday, December 8th, 2017, 10.15 – 11.00 h

Part I: Hyperkalemia – A Silent Killer?

PD Dr med. Andreas Kistler
(Spital Thurgau, Frauenfeld)

Part II: Agent in Double Mission – Treatment of Hyperkalemia and Optimization of RAAS Inhibitor Therapy

Dr med. Albin Schwarz (Stadtspital Waid, Zürich)



Meet the expert

Dr med. Albin Schwarz, Time: 13.15 h,
Vifor booth Interactive Q&A session

Simply scan
to add to
your agenda



Friday, December 8

| | | | |
|-------------|--|---|------------------|
| 10.15-11.00 | Satellite Symposium Sponsored by VIFOR |  | Room A |
| | Hyperkalemia Management in Cardio-Renal Patients | | |
| 10.15-10.35 | Hyperkalemia – A Silent Killer? Andreas Kistler, Frauenfeld | | |
| 10.35-11.00 | Agent in Double Mission – Treatment of Hyperkalemia and Optimization of RAAS Inhibitor Therapy Albin Schwarz, Zürich | | |
| 11.00-11.30 | Coffee break – Visit of the exhibition – Poster viewing | | Exhibition space |
| 11.30-12.15 | Home dialysis: situation in Europe Sponsored lecture by BAXTER |  | Room A |
| | <i>Chairs: Dominik Uehlinger, Bern; Andreas Bock, Aarau</i> | | |
| | Eric Goffin, Bruxelles (BE) | | |
| 11.30-12.15 | Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia | | Room 3E |
| | Comment adapter la prise en soins du patient à ses motivations? Où le patient va-t-il vous amener? Wie lässt sich die Betreuung des Patienten an seine Motivation anpassen? Wohin führt Sie der Patient? Come conformare le cure al paziente con le sue motivazioni? Dove ci porterà il paziente? | | |
| | Christiane Helary, Infirmière spécialiste clinique en diabétologie et formatrice en éducation thérapeutique, Geneva | | |
| 12.15-12.30 | Short break | | |

Facing the Remaining Challenges for Better Long-Term Outcomes After Kidney Transplantation

Friday, 8 December 2017, 12.30–13.15 h

Astellas Satellite Symposium at the SGN-SSN Annual Meeting 2017
49th Annual Meeting of the Swiss Society of Nephrology, 7–8 December 2017, Fribourg, Switzerland

12.30h–12.35h: **Welcome**

PD Dr. Patrizia Amico, University Hospital Basel
Prof. Dr. Manuel Pascual, Centre Hospitalier Universitaire Vaudois

12.35h–12.50h: **How can we address medication non-adherence in our kidney transplant patients?**

Prof. Dr. Dirk Kuypers, University Hospital Leuven, Leuven, Belgium

12.50h–13.05h: **Can we COMMIT to improve long-term outcomes in kidney transplantation?**

Prof. Dr. Daniel Serón, University Hospital Vall d'Hebron, Barcelona, Spain

13.05h–13.15h: **Panel Discussion**

13.15h: **Conclusions & Close**

PD Dr. Patrizia Amico & Prof. Dr. Manuel Pascual

APCHADVLB1017e

Friday, December 8

12.30-13.15

Satellite Symposium
Sponsored by **ASTELLAS**



Room A

Facing the Remaining Challenges for Better Long-Term Outcomes After Kidney Transplantation

12.30-12.35

Welcome

Patrizia Amico, Basel ; Manuel Pascual, Lausanne

12.35-12.50

How can we address medication non-adherence in our kidney transplant patients?

Dirk Kuypers, Leuven (B)

12.50-13.05

Can we COMMIT to improve long-term outcomes in kidney transplantation?

Daniel Serón, Barcelona (E)

13.05-13.15

Panel Discussion

13.15

Conclusions & Close

Patrizia Amico, Basel ; Manuel Pascual, Lausanne

12.30-13.15

Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia

Room 3E

Multidisciplinarité dans la prise en charge de la néphropathie diabétique et rôle infirmier

Multidisziplinarität bei der Behandlung der diabetischen Nephropathie und Rolle der Pflege

Pluridisciplinarità nella presa in carico della nefropatia diabetica e ruolo dell'infermiere

Dina Nobre, Infirmière de recherche pour le programme cantonal rein/diabète au CHUV, Lausanne ; Nancy Helou, Professeure HES associée, HESAV, Lausanne

13.15-14.00

Standing lunch at the exhibition – Poster viewing

Exhibition space



Friday, December 8

| | | |
|-------------|--|------------------|
| 14.00-15.00 | Oral Parallel Presentations | |
| 14.00-15.00 | Clinical Nephrology / Hypertension / Mineral / Electrolytes Room A <i>Chairs: Spyridon Arampatzis, Bern; Grégoire Würzner, Lausanne</i> 6 oral presentations | |
| 14.00-15.00 | Hemodialysis (HD) / Peritoneal Dialysis (PD) Room B <i>Chairs: Luca Gabutti, Locarno; Fabien Stucker, Neuchâtel</i> 6 oral presentations | |
| 15.00-15.30 | Coffee break – Visit of the exhibition | Exhibition space |

Oral communications

| | |
|-------------|---|
| 14.00-15.00 | Clinical Nephrology / Hypertension / Mineral / Electrolytes Room A <i>Chairs: Spyridon Arampatzis, Bern; Grégoire Würzner, Lausanne</i> |
| OC 1 | Reduced cortical oxygenation predicts progressive renal function decline in humans: results of a prospective study Dr. Menno Pruijm ¹ , Mr. Bastien Milani ¹ , Dr. Edward Pivin ¹ , Prof. Matthias Stuber ¹ , Prof. Bruno Vogt ² , Prof. Michel Burnier ¹ ¹ CHUV Lausanne, ² Inselspital, Bern |
| OC 2 | An MRI based score for assessment of fibrosis in CKD patients Dr. Lena Berchtold ¹ , Dr. Iris Friedli ² , Dr. Lindsey Crowe ² , Dr. Solange Moll ³ , Dr. Karine Hadaya ² , Dr. Thomas De Perrot ² , Prof. Pierre-Yves Martin ⁴ , Prof. Jean-paul Vallée ² , Prof. Sophie De Seigneux ¹ ¹ University Hospital Geneva, ² Geneva University Hospitals, ³ Geneva University Hospital and Medical School, ⁴ AMC/Geneva University Hospitals |
| OC 3 | Prevalences of distal renal tubular acidosis and other metabolic abnormalities among 534 non-selected kidney stone formers – a single center study Prof. Bernhard Hess ¹ , Dr. Jerzy Sromicki ² ¹ KidneyStone Center Zurich, Klinik Im Park, Zurich, ² University Hospital, Zurich |
| OC 4 | Dietary sodium intake modulates urinary potassium excretion in humans Prof. Antoinette Pechere ¹ , Dr. Khalil Udwan ² , Ms. Marinette Chiki ¹ , Dr. Lena Berchtold ¹ , Prof. Sophie De Seigneux ¹ , Prof. Pierre-Yves Martin ³ , Prof. Reto Krapf ⁴ , Prof. Johannes Loffing ⁵ , Prof. Eric Feraille ² ¹ University Hospital Geneva, ² University of Geneva, ³ AMC/Geneva University Hospitals, ⁴ University of Basel, ⁵ University of Zurich |
| OC 5 | Phenotype of kidney stone formers with renal phosphate leak Dr. Nasser Dhayat ¹ , Mr. David Lüthi ¹ , Ms. Lisa Schneider ¹ , Mr. Cedric Mattmann ¹ , Prof. Bruno Vogt ¹ , Prof. Daniel Fuster ² ¹ University of Bern, ² University of Bern, Swiss National Centre of Competence in Research (NCCR) TransCure, Bern |
| OC 6 | Prediction of kidney function after nephrectomy in donor and recipient Ms. Laura Hapuoja ¹ , Dr. Kerstin Huebel ² , Dr. Olivier De Rougemont ² , Prof. Thomas Mueller ² ¹ University of Zurich, ² University Hospital Zurich |

Oral communications

- 14.00-15.00** **Hemodialysis (HD)/Peritoneal Dialysis (PD)** **Room B**
Chairs: Luca Gabutti, Locarno; Fabien Stucker, Neuchâtel
- OC 13** **Implementation of remote patient management in the care of automated peritoneal dialysis patients in Switzerland: 18 months experience**
Dr. Valérie Jotterand Drepper¹, Prof. Pierre-Yves Martin¹, Dr. Thomas Hernandez¹, Dr. Catherine Stoermann-Chopard¹
¹AMC/Geneva University Hospitals
- OC 14** **Experience with rivaroxaban treatment in 10 haemodialysis patients**
Mr. Davide Spica¹, Dr. Beatrice Paul¹, Prof. Stephan Segerer¹, Prof. Andreas Bock¹
¹Kantonsspital Aarau
- OC 15** **Do measurements of serum ferritin and TSAT as performed in clinical practice accurately guide iv iron therapy with ferrum carboxymaltose in hemodialysis-patients?**
Mr. Matthias Diebold¹, Dr. Andreas Kistler¹
¹Kantonsspital Frauenfeld
- OC 16** **The role of ISO-9001:2008 certification for management and quality control in dialysis: the experience of a Swiss centre**
Dr. Claudia Ferrier¹, Prof. Stefano Calciolari², Prof. Mario Bianchetti³
¹Nefrocentro Clinica Luganese, NetMEGS, Università della Svizzera Italiana, Lugano, ²Istituto IdEP, Facoltà di Scienze Economiche, Università della Svizzera Italiana, Lugano, ³Facoltà di Biomedicina, Università della Svizzera Italiana, Lugano
- OC 17** **Risk factors for community-acquired Acute Kidney Injury in patients with and without chronic kidney injury and impact of its initial management on prognosis: a prospective observational study**
Dr. Patrick Saudan¹, Dr. Fabien Stucker², Dr. Belen Ponte¹, Dr. Cyrielle Alves¹, Prof. Thomas Perneger¹, Prof. Pierre-Yves Martin¹
¹Hôpitaux universitaires de Geneva, ²Hôpital de la Providence, Neuchâtel,

Oral communications

- OC 18** **Toward a better understanding of chronic kidney disease using metabolomics**
Mr. Yoric Gagnebin¹, Mr. Julian Pezzati¹, Dr. Pierre Lescuyer², Prof. Sophie De Seigneux³, Dr. Julien Broccard¹, Prof. Serge Rudaz¹, **Dr. Belen Ponte**³
¹University of Geneva and Lausanne, Geneva and Lausanne, ²Geneva University Hospitals, Geneva, ³Geneva University Hospitals and Medical School, Geneva, Switzerland

Friday, December 8

15.30-16.30

Hot Topics

Chairs: Uyen Huynh-Do, Bern; Michael Dickenmann, Basel

15.30-16.00

Kidney paired donation – The Australian experience

Paolo Ferrari, Lugano (CH)/Sydney (AU)

16.00-16.30

Hypertension targets in CKD

Michel Burnier, Lausanne

Room A

16.30

Farewell

Pierre-Yves Martin, Geneva

Poster presentations

P 1 – P 23

Clinical Nephrology / Hypertension / Mineral / Electrolytes

P 24 – P 39

Basic Science / Genetics / Experimental Nephrology

P 40 – P 46

Hemodialysis / Peritoneal Dialysis

P 47 – P 56

Transplantation

Clinical Nephrology / Hypertension / Mineral / Electrolytes

P 1

Impact of citrate supplementation on urinary risk profile in Swiss recurrent calcium stone formers (NCCR Project)

Ms. Gioia Fischer¹, Ms. Anna Wiegand¹, Dr. Harald Seeger¹, Prof. Daniel Fuster², Prof. Olivier Bonny³, Dr. Thomas Hernandez⁴, Dr. Min Jeong KIM⁵, Prof. Carsten Wagner⁶, Dr. Nilufar Mohebbi¹

¹University Hospital Zurich, ²University Hospital Bern, ³CHUV Lausanne, ⁴University Hospital Geneva, ⁵University Hospital Basel, ⁶University of Zurich

P 2

Zinc deficiency in chronic kidney disease is not related to increased urinary excretion

Dr. Philippe Braconnier¹, Dr. Sébastien Lenglet¹, Dr. Marc Augsburger¹, Prof. Michel Burnier², Prof. Aurélien Thomas³, Dr. Menno Pruijm¹

¹University Hospital (CHUV), Lausanne, ²CHUV Lausanne, ³University of Lausanne

P 3

Essential trace elements in chronic kidney disease patients in Switzerland

Dr. Philippe Braconnier¹, Dr. Sébastien Lenglet¹, Dr. Marc Augsburger¹, Prof. Michel Burnier², Prof. Aurélien Thomas³, Dr. Menno Pruijm¹

¹University Hospital (CHUV), Lausanne, ²CHUV Lausanne, ³University of Lausanne

P 4

Longitudinal follow-up of stone formers in Switzerland - NCCR Kidney.CH project

Prof. Olivier Bonny¹, Prof. Daniel Fuster², Dr. Nilufar Mohebbi³, Dr. Thomas Hernandez⁴, Dr. Min Jeong KIM⁵, Dr. Florian Buchkremer⁶, Dr. Beat Roth², Dr. Grazia Cereghetti⁷, Prof. Carsten Wagner⁸

¹University Hospital (CHUV), Lausanne, ²Inselspital Bern, ³Universitätsspital Zürich, ⁴Hôpitaux universitaires de Geneva, ⁵University Hospital Basel, ⁶Kantonsspital Aarau, ⁷NCCR Kidney.CH, Zurich, ⁸University of Zurich

Poster presentations

- P 5** **Pre-existing, Perioperative and Postoperative Chronic Kidney Disease in Patients Receiving Orthotopic Liver Transplantation**
Mr. Fabian Hauenstein¹, Dr. Guido Beldi¹, Prof. Bruno Vogt¹, Prof. Uyen Huynh-Do¹, Dr. Vanessa Banz¹, **Dr. Daniel Sidler**¹
¹University Hospital Bern
- P 6** **Change in V-ATPase B1 but not B2 subunit abundance in human urinary exosomes in response to acute acid/alkali loading and distal renal tubular acidosis**
Dr. Ganesh Pathare¹, Dr. Nasser Dhayat¹, Dr. Nilufar Mohebbi², Prof. Carsten Wagner³, Dr. Alexandru Bobulescu⁴, Prof. Orson Moe⁴, Prof. Daniel Fuster¹
¹University of Bern, ²University Hospital Zurich, ³University of Zurich, ⁴University of Texas Southwestern Medical Center, Dallas, Texas, USA
- P 7** **Lipodystrophy increases the risk of developing chronic kidney disease in HIV- positive patients in Switzerland: the LIPOKID study**
Dr. Yassine Bouatou¹, Dr. Angèle Gayet-ageron¹, Dr. Enos Bernasconi², Prof. Manuel Battegay³, Dr. Matthias Hoffmann⁴, Dr. Cornelia Staehelin⁵, Dr. Laurent Merz⁶, Dr. Helen Kovari⁷, Dr. Christoph Fux⁸, Prof. Alexandra Calmy¹, Prof. Sophie De Seigneux¹
¹University Hospital Geneva, ²Regional Hospital Lugano, Lugano, ³University Hospital Basel, ⁴Kantonsspital St. Gallen, ⁵Bern University Hospital, ⁶CHUV Lausanne, ⁷University Hospital Zurich, ⁸Kantonsspital Aarau
- P 8** **Diagnostic accuracy of immunofluorescence versus immunoperoxidase staining to distinguish immune complex-mediated glomerulonephritis and C3 dominant glomerulopathy**
Dr. Yassine Bouatou¹, Dr. Jesper Kers², Ms. Marie Chevalier Florquin², Dr. Nike Claessen², Dr. Tri N guyen³, Dr. Jeffrey Damman², Dr. Henrique Proenca⁴, Dr. Joris Roelofs², Prof. Sandrine Florquin²
¹AMC/Geneva University Hospitals, ²AMC, Amsterdam, Netherlands, ³UMCU, Utrecht, Netherlands, ⁴Universidade Metropolitana de Santos (UNIMES), Santos, Brazil
- P 9** **Medication adherence during work-up for Conn syndrome**
Dr. Jürgen Bohlender¹, Dr. Friederike Sandbaumhüter¹, Prof. Bruno Vogt¹, Prof. Manuel Haschke¹
¹Inselspital, Bern University Hospital

Poster presentations

- P 10** **An algorithm to prevent overly rapid correction of hyponatremia by urine volume monitoring**
Dr. Florian Buchkremer¹, Prof. Stephan Segerer¹, Prof. Andreas Bock¹
¹Kantonsspital Aarau
- P 11** **Renal Amyloidosis is not sufficiently prevented in patients with FMF in Armenia**
Dr. Sofi Sarinyan¹, Dr. Helen Nazaryan², Dr. Armen Sanamyan², Prof. Gayane Amaryan¹, Prof. Ernst Leumann³, Prof. Ara Babloyan², Prof. Ashot Sarkissian²
¹Yerevan State Medical University, Yerevan, Armenia, ²Arabkir Medical Centre, Yerevan, Armenia, ³University Children's Hospital, Zurich
- P 12** **Microbiological analysis of hemodialysis water at the university teaching hospital of Yaounde, Cameroon**
Dr. Cedric Gueguim¹, Dr. Alain Ragon², Prof. Francois Kaze¹, Prof. Hortense Gonsu Kamga¹
¹University of Yaounde I, Yaounde, Cameroon, ²Hospital of Conception, Marseille, France
- P 13** **NOSTONE Trial: Randomized double-blind placebo-controlled trial assessing the efficacy of standard and low dose hydrochlorothiazide treatment in the recurrence prevention of calcareous nephrolithiasis**
Dr. Patrizia Amico¹, Dr. Giulia Bedino², Prof. Olivier Bonny³, Dr. Florian Buchkremer⁴, Dr. Rosaria Del Giorno⁵, Dr. Thomas Hernandez⁶, Dr. Nasser Dhayat⁷, Dr. Nicolas Faller⁷, Prof. Luca Gabutti⁵, Dr. Carina Hüsler⁸, Dr. Irene Koneth⁸, Dr. Michael Mayr¹, Dr. Nilufar Mohebbi⁹, Dr. Urs Odermatt¹⁰, Dr. Lisa Pellegrini², Dr. Beat Roth⁷, Dr. Harald Seeger⁹, Dr. Carlo Schönholzer², Dr. Catherine Stoermann-Chopard⁶, **Dr. Luca Tamò**¹¹, Prof. Daniel Teta¹², Dr. Reto Venzin¹³, Prof. Daniel Fuster⁷
¹University Hospital Basel, ²EOC, Lugano, ³CHUV, Lausanne, ⁴Kantonsspital Aarau, ⁵EOC, Bellinzona, ⁶University Hospital Geneva, ⁷University Hospital Bern, ⁸Kantonsspital St. Gallen, ⁹University Hospital Zurich, ¹⁰Kantonsspital Luzern, ¹¹University of Bern, ¹²Hôpital Cantonal du Valais, Sion, ¹³Kantonsspital Graubünden, Chur

Poster presentations

- P 14** **hypokalemic metabolic alkalosis, hypertension and diabetes – what is the link?**
Mr. Marius Vögelin¹, Dr. Richard Cathomas¹, Dr. Niklaus Kamber¹, Prof. Thomas Fehr¹
¹Kantonsspital Graubünden, Chur
- P 15** **Single center experience with tolvaptan in nine patients with autosomal dominant polycystic kidney disease (ADPKD)**
Dr. Nina Hess¹, Dr. Emily Pollock¹, Dr. Verena Schärer¹, Dr. Claudia Kobel¹, Dr. Nina Weber¹, Dr. Alexander Ritter¹, Prof. Thomas Mueller¹, Prof. Rudolf P. Wüthrich¹, Prof. Johan Lorenzen¹
¹University Hospital Zurich
- P 16** **Could polymerase chain reaction (pcr) avert worsening acute kidney injury? a case of leptospirosis in a regional hospital**
Dr. James TATAW¹, Dr. Terezija Gracin¹, Dr. Cecile Bassi¹
¹Hôpital du Jura bernois SA, Moutier
- P 17** **Vascular aging processes accelerate during the whole life following an alarming kinetic; Pulse Wave Velocity as an objective counterpart that time flies**
Prof. Luca Gabutti¹, Dr. Rosaria Del Giorno¹
¹EOC, Bellinzona
- P 18** **A rare renal complication leading to the first diagnosis of chronic pancreatitis**
Dr. Nikolaos Drivakos¹, Dr. Cédric Pulver¹, Dr. Annette Marie Wons¹, Dr. Jörg Neuweiler¹, Dr. Françoise-Isabelle Binet¹, Dr. Dimitrios Tsinalis¹
¹Kantonsspital St. Gallen
- P 19** **Excessive consumption of “over-the-counter” vitamin D supplements leading to severe hypercalcemia and acute kidney injury: case report**
Dr. Catherine Beglinger¹, Dr. Dimitrios Tsinalis², Dr. Min Jeong KIM¹, Mrs. Karin Jung¹, Prof. Michael Brändle¹, Dr. Françoise-Isabelle Binet²
¹Cantonal Hospital St. Gallen, ²Kantonsspital St. Gallen

Poster presentations

- P 20** **mTOR Inhibitor: a new indication for a rare disease?**
Dr. Ann-Kathrin Schwarzkopf¹
¹Hirslanden Bern, Salem-Spital, Bern
- P 21** **Diabetic muscle infarction: a diagnostic challenge for clinicians and radiologists**
Mrs. Jennifer Scotti Gerber¹, Dr. Davide Giunzioni¹, Dr. Silvio Pianca¹, Prof. Jos C Van Den Berg¹, Dr. Carlo Schönholzer¹
¹Regional Hospital Lugano
- P 22** **Combined primary and secondary hyperparathyroidism in a liver transplant patient: a case report**
Dr. Curzio Solca¹, Dr. Benedetta Terziroli², Dr. Fabio Cattaneo³, Dr. Claudia Ferrier¹
¹Nefrocentro Clinica Luganese Moncucco, Lugano, ²Epatocentro, Lugano, ³Clinica Luganese Moncucco, Lugano
- P 23** **Unexplained severe lactic acidosis in a non-diabetic chronic hemodialysis patient: do you consider to make a phone call to the pharmacy?**
Ms. Céline Aeberhard¹, Dr. Ould Maouloud Hemett¹, Dr. Yvan Fleury¹, Dr. Benoit Fellay¹, Dr. Jean Luc Magnin¹, Dr. Pierre Lescuyer², Prof. Daniel Hayoz¹, Dr. Eric Descombes¹
¹HFR, Hôpital Cantonal Fribourg, ²Geneva University Hospitals
- Basic Science/Genetics/Experimental Nephrology**
- P 24** **Prevalence rates and risk factors for chronic kidney disease in sub-Saharan Africa: A pilot study in a semirural region of Tanzania**
Dr. Michael Mayr¹, **Mr. Nikolai Hodel**¹
¹University Hospital Basel
- P 25** **Lack of Fetuin-A exacerbates interstitial kidney fibrosis (NCCR project)**
Dr. Kevin Dessalle¹, Dr. Delphine Lambert¹, Dr. Stefan Rudloff², Prof. Uyen Huynh-Do³
¹Inselspital, Bern University Hospital, ²University Hospital Bern, ³Inselspital Bern

Poster presentations

- P 26** **Impact of Dietary Amino Acids on CKD Progression in Rats (NCCR project)**
Dr. Samyuktha Pillai¹, Dr. Giovanni Pellegrini¹, Prof. François Verrey¹
¹University of Zurich
- P 27** **Podocyte damage is induced by aberrantly glycosylated anti-PLA2R-IgG4 via the lectin complement pathway in membranous nephropathy**
Dr. George Haddad¹
¹University of Zurich
- P 28** **Young woman with bilateral renal hypoplasia, minor limb anomalies and massive dysfunction of sleep wake rhythm - a case report**
Dr. Lukas Gerber¹, Dr. Benno Röthlisberger¹, Dr. Jens Acker², Prof. Andreas Bock¹
¹Kantonsspital Aarau, ²Klinik für Schlafmedizin Zuzach, Bad Zuzach
- P 29** **Role of the serine protease CAP2/Tmprss4 in renal adaptation to potassium depletion (NCCR project)**
Dr. Anna Keppner¹, Dr. Darko Maric², Dr. Denise Kratschmar³, Dr. Petra Klusonova³, Dr. Jérémie Canonica², Prof. Alex Odermatt³, Dr. Gilles Crambert⁴, Prof. David Hoogewijs⁵, Prof. Edith Hummler²
¹University of Lausanne and University of Fribourg, Lausanne and Fribourg, ²University of Lausanne, ³University of Basel, ⁴French National Institute of Health and Medical Research (Inserm), Paris, France, ⁵University of Fribourg
- P 30** **Salt-sensitive hypertension in a new rat model for primary generalized glucocorticoid resistance (NCCR project)**
Dr. Sofia Verouti¹, Mr. David Ancín Del Olmo², Dr. Qing Wang³, Mrs. Anne-marie Merillat⁴, Dr. Veronica Ponce De Leon⁴, Dr. Denise Kratschmar⁵, Prof. Alex Odermatt⁵, Prof. Edith Hummler⁴
¹Inselspital, Bern, ²University of Lausanne, ³Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, ⁴University of Lausanne, ⁵University of Basel
- P 31** **Rebore the kidney - a novel model of back diffusion for acute shock related damage and acute tubular obstruction in anuric/oliguric kidneys: analysis from mathematical models**
Prof. Mark Christopher Arokiaraj¹
¹Pondicherry Institute of Medical Sciences, Pondicherry, India

Poster presentations

- P 32** **Aldosterone controls primary cilium length and Ift88 abundance via mineralocorticoid receptor in the distal segments of the kidney tubule *NCCR project***
Ms. Olga Komarynets¹, Dr. Eva Bernabeu-Dizin¹, Dr. Jan Czogalla², Dr. Khalil Udwan¹, Ms. Alexandra Chassot¹, Mr. Isabelle Roth¹, Prof. Johannes Loffing², Prof. Eric Feraille¹
¹University of Geneva, ²University of Zurich
- P 33** **Identification of a novel hepatitis E virus-genotype 3 strain from a chronic hepatitis E virus infection in a kidney transplant recipient in Switzerland**
Dr. Agnes Kneubühl¹, Mr. Bo Wang², Mr. Dominik Harms², Dr. Diana Ciardo³, Prof. Jörg Hofmann⁴, Prof. Claus-Thomas Bock²
¹Hospital Lachen, ²Robert Koch Institute, Berlin, Germany, ³Corelab Immunology Viollier AG, Allschwil, ⁴Charité, University Hospital, Berlin, Germany
- P 34** **Renal erythropoietin producing cells in vivo (NCCR Project)**
Dr. Karen Nolan¹, Mr. Willy Kuo¹, Dr. Faik Imeri¹, Dr. Svende Pfundstein¹, Dr. Irene Abreu-rodríguez¹, Mr. Patrick Spielmann¹, Prof. Edith Hummler², Dr. Claus-dieter Schuh¹, Prof. Andrew Hall¹, Prof. Vartan Kurtcuoglu¹, Dr. Carsten Scholz¹, Prof. David Hoogewijs³, Prof. Roland Wenger¹
¹University of Zurich, ²University of Lausanne, ³University of Fribourg
- P 35** **Hypoxia-induced long non-coding RNA Malat1 is dispensible for renal ischemia/reperfusion injury**
Mr. Malte Kölling¹, Dr. Celina Schauerte², Dr. Tamas Kaucsar³, Ms. Anika Hübner², Dr. Song Rong², Dr. Roland Schmitt², Dr. Inga Sörensen-Zender², Prof. Hermann Haller², Prof. Rudolf P. Wüthrich¹, Prof. Martin Zörnig⁴, Prof. Thomas Thum², Prof. Johan Lorenzen¹
¹University Hospital Zurich, Zurich, Switzerland, ²Hannover Medical School, Hannover, Germany, ³Semmelweis University, Budapest, Hungary, ⁴Georg-Speyer-Haus, Frankfurt, Germany

Poster presentations

- P 36** **Anti-oxidative role of cytoglobin in podocytes and its association with chronic kidney disease (NCCR project)**
Dr. Elisa Randi¹, Dr. Benjamin Vervaet², Mr. Stijn Vermeylen², Dr. Maria Tsachaki³, Ms. Elena Porto⁴, Dr. Maja T. Lindenmeyer⁵, Dr. Clemens D. Cohen⁵, Prof. Thomas Hankeln⁴, Dr. Andreas Kistler⁶, Prof. Sylvia Dewilde², Prof. Olivier Devuyst⁵, Prof. Alex Odermatt³, Prof. Roland Wenger⁵, Prof. David Hoogewijs⁷
¹University of Fribourg & University of Zurich, Fribourg and Zurich, ²University of Antwerp, Antwerp, Belgium, ³University of Basel, ⁴University of Mainz, Mainz, Germany, ⁵University of Zurich, ⁶Kantonsspital Frauenfeld, ⁷University of Fribourg
- P 37** **Uromodulin excretion is modulated by the calcium-sensing receptor**
Dr. Natsuko Tokonami¹, Dr. Eric Olinger¹, Prof. Pascal Houillier², Prof. Olivier Devuyst¹
¹University of Zurich, ²Paris Descartes University, Paris, France
- P 38** **The TWEAK/Fn14 pathway is required for Calcineurin Inhibitor Toxicity of the Kidneys**
Ms. Meike Claus¹, Ms. Rana Herro², Dr. Dennis Wolf², Dr. Konrad Buscher², Dr. Stefan Rudloff¹, Prof. Uyen Huynh-Do¹, Dr. Linda Burkly³, Dr. Mick Croft², **Dr. Daniel Sidler**¹
¹University Hospital Bern, ²La Jolla Institute for Allergy and Immunology, La Jolla, United States, ³Biogen, Boston, United States
- P 39** **Bone marrow transplantation improves proximal tubule dysfunction in mouse models of Dent disease**
Mr. Alkaly Gassama¹, Ms. Beatrice Paola Festa¹, Dr. Sarah Gabriel², Dr. Alessandro Luciani¹, Prof. Thomas Fehr³, Prof. Olivier Devuyst¹
¹University of Zurich, ²University of Melbourne, Victoria, Australia, ³Kantonsspital Graubünden, Chur

Poster presentations

Hemodialysis / Peritoneal Dialysis

- P 40** **ionized and total serum magnesium in hemodialysis: predictors and variability. a longitudinal cross-sectional study**
Dr. Rosaria Del Giorno¹, Dr. Hilary Riva², Mr. Gaetano Lucio Donato³, Prof. Luca Gabutti³
¹EOC Bellinzona, ²EOC Mendrisio, ³EOC Locarno
- P 41** **Clostridium ramosum - a rare cause of peritoneal dialysis related peritonitis**
Mrs. Jennifer Scotti Gerber¹, Dr. Linda Berney-Meyer², Prof. Stephan Segerer³
¹EOC Lugano, ²Universitätsspital Zürich, ³Kantonsspital Aarau
- P 42** **Is there a mortality paradox among diabetic patients within the Swiss dialysis population ?**
Ms. Rebecca Winzeler¹, Prof. Patrice M. Ambühl¹
¹Stadtspital Waid, Zurich
- P 43** **Demography of the dialysis population in Switzerland**
Ms. Rebecca Winzeler¹, Prof. Patrice M. Ambühl¹
¹Stadtspital Waid, Zurich
- P 44** **Evaluation of the relationship between muscle mass and serum myostatin levels in chronic hemodialysis patients**
Dr. Derya Koyun¹, Prof. Gokhan Nergizoglu¹, Prof. Kemal Metin Kir¹
¹Ankara University School Of Medicine, Ankara, Turkey
- P 45** **Prolonged disease-free survival after treatment of a bilateral breast granulocytic sarcoma with low-dose sorafenib in a chronic hemodialyzed patient**
Ms. Julie Robert¹, Dr. Ould Maouloud Hemett¹, Dr. Merryl Cassat¹, Dr. Gaëlle Rhyner¹, Dr. Eric Descombes¹, Prof. Daniel Betticher¹
¹HFR, Hopital Cantonal de Fribourg
- P 46** **Safety first, fistula second!**
Dr. Sandra Edith Knych¹, Dr. Georg-Wilhelm Meier-Fiorese¹, Dr. Felix Burkhalter¹
¹Kantonsspital Baselland, Liestal

Poster presentations


Transplantation

- P 47** **Role of Immune-Senescence in the development of de-novo Donor-Specific Antibodies after Kidney Transplantation**
Dr. Seraina von Moos¹, Dr. Gesa Schalk², Dr. Guido F. Laube², Prof. Thomas Mueller¹
¹Universitätsspital Zürich, ²Universitäts Kinderspital Zürich
- P 48** **Postoperative Seroma after Kidney Transplantation: Identification of donor-, recipient- and procedure-associated risk factors**
Mr. Ruhin Parsa¹, Dr. Spiridon Arampatzis¹, Dr. Guido Beldi¹, Dr. Suzan Dahdal¹, Ms. Angela Buechel¹, Prof. Bruno Vogt¹, Prof. Uyen Huynh-Do¹, Dr. Vanessa Banz¹, **Dr. Daniel Sidler**¹
¹University Hospital Bern
- P 49** **Safety of Early RAS Blockade in Kidney Transplant Recipients**
Mr. Luca Valente¹, Dr. Spiridon Arampatzis¹, Dr. Mariam Semmo¹, Prof. Bruno Vogt¹, Prof. Uyen Huynh-Do², **Dr. Daniel Sidler**¹
¹University Hospital Bern, ²Inselspital Bern
- P 50** **Antibody-mediated rejection triggered by parvovirus B19 infection? A case report**
Dr. Melanie Schönenberger¹, Dr. Patricia Hirt-Minkowski¹, Dr. Helmut Hopfer¹, Dr. Thomas Menter¹, Prof. Stefan Schaub¹, Dr. Katrin König¹
¹University Hospital Basel 1
- P 51** **Transplant Glomerulopathy and Arteriolohyalinosis in Renal Allograft Biopsies: Correlation between Histopathology and Clinical Outcome**
Mr. Jannick Schneuwly¹, Dr. Vera Genitsch², Prof. Bruno Vogt¹, Prof. Uyen Huynh-Do¹, **Dr. Daniel Sidler**¹
¹University Hospital Bern, ²University of Bern
- P 52** **Relationship of serum bicarbonate levels with 1-year graft function in kidney transplant recipients**
Ms. Anna Wiegand¹, Dr. Nicole Graf², Dr. Marco Bonani¹, Dr. Diana Frey¹, Prof. Rudolf P. Wüthrich¹, Dr. Nilufar Mohebbi¹
¹University Hospital Zurich, ²Graf Biostatistics, Winterthur

Poster presentations

- P 53** **Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study)**
Ms. Anna Wiegand¹, **Dr. Alexander Ritter**¹, Dr. Nicole Graf², Dr. Karine Hadaya³, Dr. Spyridon Arampatzis⁴, Prof. Thomas Mueller¹, Prof. Carsten Wagner⁵, Prof. Rudolf P. Wüthrich¹, Dr. Nilufar Mohebbi¹
¹University Hospital Zurich, ²Graf Biostatistics, Winterthur, ³Geneva University Hospitals, ⁴Inselspital Bern, ⁵University of Zurich
- P 54** **The humoral long-term progression of kidney function in patients with and without humoral allograft response**
Dr. Seraina von Moos¹, Dr. Pietro E. Cippà², Mr. Robert Van Breemen¹, Prof. Thomas Mueller¹
¹Universitätsspital Zürich, ²University of Southern California, Los Angeles, United States
- P 55** **Rituximab induces “false” positive complement-dependent cytotoxic B cells crossmatches**
Dr. Karine Hadaya¹, Mr. Johan Geiser², Prof. Thierry Berney², Prof. Pierre-Yves Martin³, Prof. Jean Villard², Dr. Sylvie Ferrari-Lacraz²
¹Geneva University Hospitals, ²Geneva University Hospital and Medical School, ³AMC/Geneva University Hospitals
- P 56** **Activability of circulating Tfh17 predicts humoral response to thymus-dependent antigens**
Dr. Suzan Dahdal¹, Ms. Carole Saison¹, Dr. Martine Valette², Prof. Bruno Lina³, Prof. Guillaume Monneret⁴, Dr. Thierry Defrance⁵, Prof. Emmanuel Morelon⁶, Prof. Olivier Thaunat⁴
¹French National Institute of Health and Medical Research (Inserm) Unit 1111, Lyon, France, ²Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France, ³Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France, ⁴Hospices Civils de Lyon, Edouard Herriot University Hospital, Lyon, France, ⁵French National Institute of Health and Medical Research (Inserm), Lyon, France, ⁶Hospices Civils de Lyon, Edouard Herriot University Hospital, Department of Transplantation, Lyon, France

Plan of exhibition



Exhibitors

| Company | Booth |
|--|-------|
| Abbvie AG | 19 |
| AIRG | 3B |
| Alexion Pharma GmbH | 23 |
| Amgen Switzerland AG | 24 |
| Astellas Pharma AG | 5 |
| Baxter AG | 17 |
| B. Braun Medical AG | 10 |
| Bracco Suisse SA | 7 |
| CytoSorbents Switzerland GmbH | 18 |
| Diavantis | 4C |
| Forni medical gmbh | 13 |
| Fresenius Medical Care (Schweiz) AG | 24 |
| Laboratorium Dr G. Bichsel AG | 21 |
| MCM MEDSYS AG | 4B |
| medi-lan ag | 22 |
| Mitsubishi Tanabe Pharma GmbH | 16 |
| Neovii Pharmaceuticals AG | 4A |
| Novartis Pharma Schweiz AG | 15 |
| Otsuka Pharmaceutical (Switzerland) GmbH | 1 |
| Pro Farma AG | 11 |
| Roche Pharma (Schweiz) AG | 8 |
| Salmon Pharma GmbH | 12 |
| Sandoz Pharmaceuticals AG | 15 |
| sanofi-aventis (schweiz) ag | 14 |
| Schweizer Dialyseregister | 3A |
| Shire Switzerland GmbH | 25 |
| Terumo BCT Europe N.V. | 6 |
| theramed ag | 20 |
| Vifor SA | 9/2B |
| VNPS | 3C |

Speakers / Moderators

Ambühl Patrice, Zürich
Amico Patrizia, Basel
Arampatzis Spyridon, Bern
Bichet Daniel G., Montreal (CA)
Bock Andreas, Aarau
Bonny Olivier, Lausanne
Burnier Michel, Lausanne
De Seigneux Sophie, Geneva
De Zélicourt Diane, Zürich
Devuyst Olivier, Zürich
Dickenmann Michael, Basel
Dufey-Teso Anne, Geneva
Ernandez Thomas, Geneva
Ferrari Paolo, Lugano/Sydney (AU)
Fischer Andreas, Lucerne
Fuster Daniel, Bern
Gabutti Luca, Locarno
Gaspert Ariana, Zürich
Genitsch-Gratwohl Vera, Bern
Goffin Eric, Bruxelles (BE)
Hadaya Karine, Geneva
Halabi Georges, Lausanne
Hamer Rizwan, Coventry (GB)
Hayoz Daniel, Fribourg
Helary Christiane, Geneva
Helou Nancy, Lausanne
Hopfer Helmut, Basel
Huynh-Do Uyen, Bern
Jotterand Drepper Valérie, Geneva
Kistler Andreas, Frauenfeld
Kurschat Christine, Köln (DE)
Kuypers Dirk, Leuven (BE)
Lambie Mark, Stokes (GB)
Lefuel Pascale, Geneva
Loffing Johannes, Zürich
Lorenzen Johan, Zürich
Martin Pierre-Yves, Geneva
Menter Thomas, Basel
Mohebbi Nilufar, Zürich
Moll Solange, Geneva
Müller Thomas, Zürich
Nobre Dina, Lausanne
Pascual Manuel, Lausanne
Ponte Belen, Geneva
Pruijm Menno, Lausanne
Ricklin Daniel, Basel
Rotman Samuel, Lausanne
Scholz Carsten, Zürich
Schwarz Albin, Zürich
Seron Daniel, Barcelona (ES)
Stoermann-Chopard Catherine, Geneva
Stucker Fabien, Neuchâtel
Tschumi Sibylle, Bern
Uehlinger Dominik, Bern
Villard Jean, Geneva
Wagner Carsten, Zürich
Würzner Grégoire, Lausanne
Zeerleder Sacha, Amsterdam (NL)

Association

Association pour l'Information et la Recherche sur les maladies rénales Génétiques (AIRG)



Verband Nierenpatienten Schweiz (VNPS)

Kind thanks to the municipality of Granges-Paccot, as well as to the State of Fribourg, for their financial support and welcome



ETAT DE FRIBOURG
STAAT FREIBURG

Sponsored in alphabetical order

Symposia



Amgen Switzerland AG

Satellite Symposium
Thursday, December 7, 2017 – 12.30-13.15/Room A



Astellas Pharma AG

Satellite Symposium
Friday, December 8, 2017 – 12.30-13.15/Room A



Baxter AG

Parallel Satellite Symposium
Thursday, December 7, 2017 – 15.30-16.15/Room A



Otsuka Pharmaceutical (Switzerland) GmbH

Parallel Satellite Symposium
Thursday, December 7, 2017 – 15.30-16.15/Room B



Vifor SA

Satellite Symposium
Friday, December 8, 2017 – 10.15-11.00/Room A

Lectures

It is a support of a 30-minute session based on the scientific program, the sponsor has no influence neither on the content nor on the choice of the speakers (responsibility of the SSN)



Alexion Pharma GmbH

Sponsored lecture
Thursday, December 7, 2017 – 14.00-15.00/Room A



Baxter AG

Sponsored lecture
Friday, December 8, 2017 – 11.30-12.15/Room A



Shire Switzerland GmbH

Sponsored lecture
Thursday, December 7, 2017 – 17.10-17.40/Room B

Advertisement

sanofi-aventis (schweiz) ag

Kind thanks to all our sponsors



Kind thanks to all our sponsors

NephroFlow[®]

 Mitsubishi Tanabe Pharma GmbH

neovii

 **NOVARTIS**


Otsuka


PRO FARMA


Roche

Salmon Pharma
Ein Unternehmen der

MEDICE

SANDOZ A Novartis
Division


Shire


SANOFI


SANOFI GENZYME


swiss renal registry and quality assessment program

TERUMOBCT
Unlocking the Potential of Blood


theramed ag
medizinprodukte

 **VIFOR
PHARMA**

Save the date: SGN-SSN congress 2018

We would like to invite you to the

50th Annual Meeting of the Swiss Society of Nephrology SGN-SSN
on **December 6-7, 2018** – Congress Centre Kursaal Interlaken



Please save the dates of December 6-7, 2018!

We look forward to welcoming you in Interlaken next year!

NEPHRO
SWISS SOCIETY OF NEPHROLOGY
www.swissnephrology.ch

Schweizerische Gesellschaft für Nephrologie
Société Suisse de Néphrologie
Società Svizzera di Nefrologia

RENVELA®

Your partner against hyperphosphatemia¹



Calcium-free



Metal-free^{*}



Not absorbed^{**}

Right from the start.

RenVela
Sevelamercarbonat

¹ Active substance without metals or calcium. Sevelamer carbonate is a polymer that is not absorbed in the gastrointestinal tract.

^{**} In a one-year clinical study, no evidence of sevelamer accumulation was found.

Renvela® Film-coated tablets 800 mg and powder 2.4 g. **DS:** Sevelamer carbonate. **E:** Adults: hyperphosphatemia in patients undergoing haemodialysis or peritoneal dialysis and nonhaemodialysis-dependent patients with chronic renal insufficiency and serum phosphorus levels of ≥ 1.75 mmol/L. For use in multipart treatment. **D:** 2.4 g or 4.8 g per day (initial dose) spread over three meals. Average approx. 6 g/day with continuous treatment. Drink suspension within 30 minutes of preparation. **CE:** Hypersensitivity to an active substance, hyperphosphatemia, bowel obstruction. **WP:** Children and adolescents under 18 years of age, non-haemodialysis-dependent patients with chronic renal insufficiency and serum phosphorus level ≤ 1.75 mmol/L, patients with dyspepsia, peptic ulcers, severe gastrointestinal motility dysfunction (including untreated or severe gastroparosia, retention of stomach content and abnormal or irregular bowel movement), active inflammatory bowel disease, major surgery on the gastrointestinal tract, obstruction bowel occlusion, ileus/prolapse, reduced absorption of liposoluble vitamins (A, D, E and K), folate deficiency, hypo-/hypercalcemia, metabolic acidosis, pyelitis, simultaneous use of anticholinergic and antispasmodic drugs, hypothyroidism, long-term chronic treatment (>3 year) with sevelamer, hyperparathyroidism. **IA:** Reduced calciparine, erythropoietin and heparin levels in transplant patients. Monitor TSH level when administering levothyroxine. Particular caution is required with patients using antiepileptic or antiarrhythmic drugs. Renvela is not absorbed and can affect the bioavailability of other drugs. There are no to be given at least one hour before or three hours after Renvela. **SE:** very common: nausea, vomiting, pain in the upper abdomen, obstruction; frequent: diarrhoea, dyspepsia, flatulence, stomach pain. **PS:** Renvela Film-coated tab., 800 mg tbl., 180 pcs. Renvela powder 2.4 g pouch 60 pcs. **Med. class:** B. **MAH:** Sanofi-Aventis (Switzerland) AG, 1214 Venney GE. **Updated:** Film-coated tablets: March 2017, powder: March 2017 (SACH.SEC.17.09.0511). For further specialised information please visit www.swissmedinfo.ch.